Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Dickinson

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly menMarcel van Gelderen, Reiner Tretter, John Meijer, et al.
Future Microbiology|September 1, 2021
Age and sex-specific incidence rates of group A streptococcal pharyngitis between 2010 and 2018: a population-based studyKwadwo Mponponsuo, Deirdre L Church, Sheng Jie Lu, et al.
Therapeutic Drug Monitoring|March 13, 2012
Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trialZbigniew Wlodarczyk, Marek Ostrowski, Michel Mourad, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 4, 2013
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprololWalter Krauwinkel, James Dickinson, Marloes Schaddelee, et al.
Clinical Transplantation|March 16, 2017
Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudyBo-Göran Ericzon, Evaristo Varo, Pavel Trunečka, et al.
International Journal of Dermatology|April 2, 2009
The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitisSakari Reitamo, Johanna Mandelin, Andris Rubins, et al.
International Journal of Dermatology|September 20, 2011
Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label studyJohanna M Mandelin, Andris Rubins, Anita Remitz, et al.
Pharmacoepidemiology and Drug Safety|October 22, 2008
National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuseStephen F Butler, Simon H Budman, Andrea Licari, et al.
Clinical Drug Investigation|December 5, 2012
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegronJames Dickinson, Michaelene Lewand, Taiji Sawamoto, et al.
Intensive Care Medicine Experimental|June 18, 2023
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patientsEndry H T Lim, Alexander P J Vlaar, Sanne de Bruin, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly menMarcel van Gelderen, Reiner Tretter, John Meijer, et al.
Future Microbiology|September 1, 2021
Age and sex-specific incidence rates of group A streptococcal pharyngitis between 2010 and 2018: a population-based studyKwadwo Mponponsuo, Deirdre L Church, Sheng Jie Lu, et al.
Therapeutic Drug Monitoring|March 13, 2012
Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trialZbigniew Wlodarczyk, Marek Ostrowski, Michel Mourad, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 4, 2013
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprololWalter Krauwinkel, James Dickinson, Marloes Schaddelee, et al.
Clinical Transplantation|March 16, 2017
Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudyBo-Göran Ericzon, Evaristo Varo, Pavel Trunečka, et al.
International Journal of Dermatology|April 2, 2009
The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitisSakari Reitamo, Johanna Mandelin, Andris Rubins, et al.
International Journal of Dermatology|September 20, 2011
Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label studyJohanna M Mandelin, Andris Rubins, Anita Remitz, et al.
Pharmacoepidemiology and Drug Safety|October 22, 2008
National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuseStephen F Butler, Simon H Budman, Andrea Licari, et al.
Clinical Drug Investigation|December 5, 2012
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegronJames Dickinson, Michaelene Lewand, Taiji Sawamoto, et al.
Intensive Care Medicine Experimental|June 18, 2023
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patientsEndry H T Lim, Alexander P J Vlaar, Sanne de Bruin, et al.
Pageof 3